Daniel Haders II

Dr. Daniel Haders II, CEO of Model Medicines, dives into the revolutionary world of AI in drug discovery. He discusses building an AI-native engine to tackle traditional drug development challenges and identifies elusive binding pockets. The conversation highlights the company's innovative MDL-001, a pan-antiviral medication, and the importance of combining hit rates with novelty. Haders emphasizes that generalizability is key for AI's role in biotech, offering a fresh perspective on the future of pharmaceutical advancements.